comprehensive -WSS

comprehensive

author：explore 2025-09-28 19:18:52 - browse：41683

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Woman gored by Bison at Yellowstone

knowledge

hotspot

WSS

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Involuntary treatment for addiction doesn't work

U.K. considers world's first use of meningitis vaccine to address gonorrhea

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

hotspot

comprehensive

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Malaria cases in Florida and Texas: Here’s what you need to know

Hospitals look to new technology to keep health care workers safe

Psychedelics group wrestles with new pharma identity

The new HIV moral panic

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

How one medical school became remarkably diverse

Congress: Eradicate hepatitis C and reduce the deficit

explore

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Congress likely to miss an opportunity to fix drug shortages issue

FDA's Woodcock to retire early next year

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Woman gored by Bison at Yellowstone

hotspot

knowledge

hotspot

leisure time